vs
Side-by-side financial comparison of Eos Energy Enterprises, Inc. (EOSE) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $58.0M, roughly 1.2× Eos Energy Enterprises, Inc.). Viridian Therapeutics, Inc.\DE runs the higher net margin — -49.0% vs -207.7%, a 158.7% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 699.6%). Eos Energy Enterprises, Inc. produced more free cash flow last quarter ($-75.2M vs $-84.7M).
Eos Energy Enterprises, Inc. is an energy storage solutions provider that designs, produces and deploys safe long-duration zinc-based battery systems. It serves utility, commercial, industrial and microgrid customers across North America, Europe and Asia, supporting grid stability and renewable energy integration.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
EOSE vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $58.0M | $70.6M |
| Net Profit | $-120.5M | $-34.6M |
| Gross Margin | -93.8% | — |
| Operating Margin | -140.1% | -56.7% |
| Net Margin | -207.7% | -49.0% |
| Revenue YoY | 699.6% | 81958.1% |
| Net Profit YoY | 55.1% | 54.9% |
| EPS (diluted) | $-0.53 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $58.0M | — | ||
| Q3 25 | $30.5M | $70.6M | ||
| Q2 25 | $15.2M | — | ||
| Q1 25 | $10.5M | — | ||
| Q4 24 | $7.3M | — | ||
| Q1 23 | $8.8M | — |
| Q4 25 | $-120.5M | — | ||
| Q3 25 | $-641.4M | $-34.6M | ||
| Q2 25 | $-222.9M | — | ||
| Q1 25 | $15.1M | — | ||
| Q4 24 | $-268.1M | — | ||
| Q1 23 | $-71.6M | — |
| Q4 25 | -93.8% | — | ||
| Q3 25 | -111.2% | — | ||
| Q2 25 | -203.2% | — | ||
| Q1 25 | -234.7% | — | ||
| Q4 24 | -324.0% | — | ||
| Q1 23 | -204.9% | — |
| Q4 25 | -140.1% | — | ||
| Q3 25 | -200.6% | -56.7% | ||
| Q2 25 | -419.1% | — | ||
| Q1 25 | -506.2% | — | ||
| Q4 24 | -712.8% | — | ||
| Q1 23 | -433.1% | — |
| Q4 25 | -207.7% | — | ||
| Q3 25 | -2102.1% | -49.0% | ||
| Q2 25 | -1463.2% | — | ||
| Q1 25 | 144.7% | — | ||
| Q4 24 | -3696.7% | — | ||
| Q1 23 | -810.4% | — |
| Q4 25 | $-0.53 | — | ||
| Q3 25 | $-4.91 | — | ||
| Q2 25 | $-1.05 | — | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-2.30 | — | ||
| Q1 23 | $-0.82 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $568.0M | $490.9M |
| Total DebtLower is stronger | $813.3M | — |
| Stockholders' EquityBook value | $-2.2B | $503.0M |
| Total Assets | $885.2M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $568.0M | — | ||
| Q3 25 | $58.7M | $490.9M | ||
| Q2 25 | $120.2M | — | ||
| Q1 25 | $82.6M | — | ||
| Q4 24 | $74.3M | — | ||
| Q1 23 | $16.1M | — |
| Q4 25 | $813.3M | — | ||
| Q3 25 | $448.5M | — | ||
| Q2 25 | $445.3M | — | ||
| Q1 25 | $325.5M | — | ||
| Q4 24 | $316.9M | — | ||
| Q1 23 | $209.8M | — |
| Q4 25 | $-2.2B | — | ||
| Q3 25 | $-2.3B | $503.0M | ||
| Q2 25 | $-1.1B | — | ||
| Q1 25 | $-942.2M | — | ||
| Q4 24 | $-1.1B | — | ||
| Q1 23 | $-175.6M | — |
| Q4 25 | $885.2M | — | ||
| Q3 25 | $328.2M | $577.1M | ||
| Q2 25 | $361.0M | — | ||
| Q1 25 | $263.3M | — | ||
| Q4 24 | $260.3M | — | ||
| Q1 23 | $99.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.3M | $-84.6M |
| Free Cash FlowOCF − Capex | $-75.2M | $-84.7M |
| FCF MarginFCF / Revenue | -129.7% | -120.1% |
| Capex IntensityCapex / Revenue | 43.1% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-265.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.3M | — | ||
| Q3 25 | $-65.9M | $-84.6M | ||
| Q2 25 | $-66.1M | — | ||
| Q1 25 | $-28.9M | — | ||
| Q4 24 | $-42.7M | — | ||
| Q1 23 | $-30.5M | — |
| Q4 25 | $-75.2M | — | ||
| Q3 25 | $-82.7M | $-84.7M | ||
| Q2 25 | $-73.2M | — | ||
| Q1 25 | $-33.8M | — | ||
| Q4 24 | $-55.8M | — | ||
| Q1 23 | $-33.4M | — |
| Q4 25 | -129.7% | — | ||
| Q3 25 | -271.1% | -120.1% | ||
| Q2 25 | -480.2% | — | ||
| Q1 25 | -323.6% | — | ||
| Q4 24 | -769.1% | — | ||
| Q1 23 | -377.8% | — |
| Q4 25 | 43.1% | — | ||
| Q3 25 | 55.2% | 0.2% | ||
| Q2 25 | 46.2% | — | ||
| Q1 25 | 47.0% | — | ||
| Q4 24 | 180.6% | — | ||
| Q1 23 | 32.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -1.91× | — | ||
| Q4 24 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
